Existing levodopa therapies for Parkinson’s disease often provide inadequate symptom control after prolonged treatment. This study assessed the cost-effectiveness of an extended-release carbidopa-levodopa formulation (IPX066).
Renée J.G. Arnold, PharmD, RPh
Advertisement
Articles by Renée J.G. Arnold, PharmD, RPh
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Extended-Release Carbidopa-Levodopa for Advanced Parkinson's Disease
Published: February 21st 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Blenrep Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
2
CHEST 2025: Advancing Respiratory Virus Vaccines and Improving Uptake Among High-Risk Populations
3
Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms Across OASIS Clinical Trials
4
G-CSF is a Potential Alternative in Treatment of Hot Flashes in Postmenopausal Women
5
